Application of mPEG-PCL-mPEG Micelles for Anti-Zika Ribavirin Delivery

Area of Science:

• Nanomedicine
• Polymer Chemistry
• Virology

Background:

• Current metal-based nanoparticles for drug delivery raise toxicity concerns due to poor biocompatibility.
• Developing safe and effective nanocarriers is crucial for advanced nanomedicine applications.
• Biocompatible polymer-based micellar nanoparticles (MNPs) offer a promising alternative.

Purpose of the Study:

• To develop a novel, biocompatible, triblock polymer nanoparticle system for targeted antiviral drug delivery.
• To create a pH-sensitive nanocarrier that releases the antiviral drug ribavirin intracellularly.
• To evaluate the efficacy and safety of these nanoparticles against Zika virus in vitro.

Main Methods:

• Synthesis of methoxy poly(ethylene-glycol)-poly(ɛ-caprolactone)-methoxy poly(ethylene glycol) (mPEG-PCL-mPEG) triblock copolymers.
• Encapsulation of ribavirin within the self-assembled micellar nanoparticles (MNPs).
• Assessment of nanoparticle dissociation and drug release at endosomal pH (5.49).
• Evaluation of antiviral activity against Zika virus in JEG-3 cells using plaque reduction assays and RT-PCR.

Main Results:

• The developed ribavirin-loaded MNPs effectively released the drug at pH 5.49, mimicking endosomal conditions.
• Significant suppression of Zika virus was observed in JEG-3 cells treated with ribavirin-loaded MNPs.
• The antiviral efficacy was achieved with approximately 90% less ribavirin compared to unencapsulated drug controls.
• Plaque reduction assays and RT-PCR confirmed the antiviral effect and showed no undue toxicity.

Conclusions:

• The novel mPEG-PCL-mPEG based micellar nanoparticles represent a safe and effective drug delivery system for antiviral agents.
• This pH-sensitive nanocarrier system demonstrates significant potential for targeted delivery and enhanced efficacy of ribavirin against Zika virus.
• The developed platform suggests a broader applicability for combating other viral pathogens.